Schizophrenia
Conditions
Keywords
schizophrenia
Brief summary
A Clinical Study that will look at an investigational medication, SEP-363856 (called study medication) in patients with schizophrenia and assess whether it changes: * how the body processes (uses) glucose (blood sugar) * how much insulin the pancreas can make. Insulin is a hormone that lowers blood sugar levels in the body. The information from this study will help to understand any effect the study medication may have on how the body uses and stores glucose. This study is accepting both male and female subjects. It will be held in approximately 6 locations in the United States. Participation could last up to 12 weeks.
Detailed description
This is an open-label, fixed sequence, multiple dose design. Following screening evaluations, subjects will check-in to the clinical research unit. After confirmation of continuation criteria, subjects will undergo an oral glucose tolerance test (oGTT), mixed meal tolerance test (MMTT) and spirulina breath test (GEBT). After these assessments are completed, subjects will have their prior antipsychotic (PA) or any other medication with psychotropic propensity washed out (dependent on their antipsychotic elimination half-life). Subjects will undergo SEP-363856 titration schedule, followed by the oGTT, MMTT and GEBT tests during the SEP-363856 Stable Dose Period. Subjects will be stabilized on their prior antipsychotic, discharged from the clinical research unit, and return to the unit for the follow-up visit 7 + 2 days after discharge.
Interventions
DRUGSEP-363856
SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
Sponsors
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an open-label, fixed sequence, multiple dose design.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
(this list is not all inclusive) * Male or female subjects between 18 and 65 years of age, inclusive at time of consent. * Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview, using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-5, Clinical Trials Version \[SCID-CT\]). * Subject must have a CGI-S score ≤ 4 (normal to moderately ill) at Screening * Subject must have a PANSS total score ≤ 80 at Screening and a score of ≤ 4 on the following PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness) * Subjects' antipsychotic medication at screening must have had no dose change (minor dose adjustments for tolerability purposes are permitted) for at least eight weeks prior to the Screening visit.
Exclusion criteria
(this list is not all inclusive) \-- Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia or intellectual disability (IQ \< 70). * Subject has attempted suicide within 12 months prior to Screening. * Subject answers yes to Suicidal Ideation Items 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at Screening (ie. in the past 1 month) or at any subsequent C-SSRS assessment prior to dosing (ie, since last visit). * Subject is at risk of harming him/herself or others according to the Investigator's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline (PA) in oGTT derived plasma AUC0-120 min of glucose, insulin, c-peptide in oGTT to stable dose (SEP-363856) period assessment. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) |
| Change from baseline (PA) in mixed meal tolerance test (MMTT) derived plasma AUC0-240 min of glucose, insulin, c-peptide and β-cell responsivity index to stable dose (SEP-363856) period assessment. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in lag time, baseline to stable dose (SEP-363856) period assessment | PA Baseline and SEP-363856 Stalbe Dose Period (up to 48 days) | — |
| Change from baseline (PA) in plasma AUC0-240 min and Cmax of acetaminophen levels to stable dose (SEP-363856) period assessment. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) | — |
| Change in kPCD, baseline to stable dose (SEP-363856) period assessment | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) | — |
| Change in gastric emptying terminal elimination half-life (T1/2), baseline to stable dose (SEP-363856) period assessment. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) | — |
| Change in Cmax of acetaminophen levels to stable dose (SEP-363856) period assessment. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) | — |
| Change in the Visual Analog Scale (VAS) of fullness, hunger and satiety, baseline - repeat test (PA baseline to SEP-363856 stable dose period assessment) for all time points. | PA Baseline and SEP-363856 Stable Dose Period (up to 48 days) | Visual Analog Scale (VAS) is on a scale of 0-100, higher represents higher pain intensity (higher score represents worse outcome). |
Countries
United States
Outcome results
None listed